Press Releases
Archives
Public Relations Contacts
Font Size:
December 12, 2006
ABILIFY® (aripiprazole) Injection for Intramuscular Use For Adults with Agitation Associated with Schizophrenia or Bipolar Mania Now Available
December 7, 2006
ABILIFY® (aripiprazole) Demonstrated Efficacy as Long-Term Maintenance Therapy in Adults with Bipolar I Disorder Following Treatment For a Recent Manic or Mixed Episode
September 7, 2006
Helping Hands Grants Support Community Mental Health Programs, Funded by Otsuka America Pharmaceutical, Inc.
August 17, 2006
Bristol-Myers Squibb and Otsuka Pharmaceutical Company Launch New Rapidly Disintegrating Oral Antipsychotic Medication ABILIFY® DISCMELT™ (aripiprazole)
May 30, 2006
American Psychiatric Foundation Announces Recipients of 2006 Awards for Advancing Minority Mental Health - Supported by a Grant from Otsuka America Pharmaceutical, Inc.
May 25, 2006
Six-Month Study Evaluated Effectiveness of Aripiprazole and Standard of Care in Management of Community-Treated Patients with Schizophrenia
May 16, 2006
ABILIFY
®
(aripiprazole) Demonstrated Efficacy as Maintenance Therapy in Adults with Bipolar I Disorder Following Treatment for a Recent Manic or Mixed Episode
March 13, 2006
American Psychiatric Foundation Announces Recipients of Inaugural Helping Hands Grants - Supported by a Grant by Otsuka America Pharmaceutical, Inc.
February 7, 2006
Bristol-Myers Squibb Company and Otsuka Pharmaceutical, Co., Ltd. Announce Availability of 2mg (aripiprazole) Tablet and Nonrefrigerated Oral Solution
August 18, 2005
American Psychiatric Foundation’s Awards for Advancing Minority Mental Health Is Seeking Applicants for its 2005 Program
August 15, 2005
Otsuka Announces Support of Helping Hands Grant Program
June 1, 2005
Otsuka Celebrates 20 Successful Years In Maryland
May 25, 2005
New Investigational Data Using Intramuscular Administration of Aripiprazole in Patients with Acute Bipolar Mania and Schizophrenia
May 18, 2005
Multiple Studies at DDW Report on Adacolumn
®
Apheresis Device in Treating Inflammatory Bowel Disease
April 26, 2005
Otsuka America Pharmaceutical, Inc. Launches National and Local Initiatives to Eliminate Minority Health Disparities
April 1, 2005
Hiromi Yoshikawa, Chairman and CEO of Otsuka America Pharmaceutical, Inc. Joins PhRMA Board of Directors
March 23, 2005
American Psychiatric Foundation Announces 2004 Recipients of Awards for Advancing Minority Mental Health
March 7, 2005
Abilify
®
(aripiprazole) Granted Approval for New Indication
January 4, 2005
FDA Provides Oral Solution Formulation of Abilify
®
(aripiprazole)
December 21, 2004
American Heart Association Presents Arteriosclerosis/Heart Failure Research Prize.
October 7, 2004
Otsuka America Pharmaceutical, Inc. Enters Co-Promotion Alliance with Santarus, Inc
October 1, 2004
FDA Approves Abilify
®
(aripiprazole) for Treatment of Acute Bipolar Mania, Including Manic and Mixed Episodes
September 21, 2004
Terry Prime Promoted to Vice President, Marketing of Otsuka America Pharmaceutical, Inc.
September 15, 2004
Otsuka America Pharmaceutical, Inc. Receives Frost & Sullivan’s 2004 Product Innovation of the Year Award for Antipsychotic Medications
August 10, 2004
Otsuka’s Adacolumn
®
Device to Enter Pivotal Study in Crohn’s Disease
May 18, 2004
Data Presented at Digestive Disease Week on Two Otsuka Products in Development for Inflammatory Bowel Disease
May 5, 2004
New Data and Analyses Demonstrate Abilify
®
(aripiprazole) Effective at Treating Patients with Acute Manic and Mixed Episodes of Bipolar Disorder
May 5, 2004
Clinical Study Shows Intramuscular Administration of Aripiprazole (Abilify
®
) Significantly Improves Acute Agitation in Patients with Schizophrenia
April 13, 2004
American Psychiatric Foundation Presents First-Ever Minority Mental Health Awards
April 7, 2004
Otsuka's Adacolumn
®
Device to Enter Pivotal Study in Ulcerative Colitis
November 14, 2003
Study Shows 40 Percent Relative Risk Reduction in Coronary Stent Blockage with Cilostazol Added to Standard Therapy
September 8, 2003
FDA Approveds Abilify ® (aripiprazole) Supplemental New Drug Application (sNDA for Maintaining Stability in Patients with Schizophrenia
July 16, 2003
Supplemental New Drug Application Submitted for Abilify (aripiprazole) for the Treatment of Acute Bipolar Mania
May 20, 2003
Results from New Clinical Studies: Aripiprazole Significantly Improved Symptoms of Acute Bipolar Mania
May 19, 2003
Aripiprazole Demonstrates Better Weight Change Profile, Comparable Efficacy in Schizophrenia Compared to Olanzapine in New Study
May 12, 2003
Otsuka Teams with American Psychiatric Foundation for New Minority Mental Health Awards Program
February 25, 2003
Supplemental New Drug Application (sNDA) for Long-Term Schizophrenia Treatment Submitted for Abilify (aripirprazole)
* OAPI, OPDC, and OMML are subsidiaries of Otsuka America, Inc. (OAI), a holding company established by OPC in the U.S. in 1989